COMPANY

Daniel Cohen, Ph.D., is the CEO and Co-founder of 3DBio Therapeutics. Prior to 3DBio, Daniel was an Engagement Manager at McKinsey & Company in New York, where he focused on manufacturing, industrials, healthcare, and 3D printing. He received his Ph.D., as well as B.S. and M.S. degrees, in Mechanical Engineering from Cornell University, with minors in Biomedical and Electrical Engineering. Dr. Cohen was awarded both the National Science Foundation Graduate Research Fellowship, and the Department of Homeland Security Graduate Fellowship. At Cornell, he focused on bioprinting technology, completing his doctoral dissertation on 3D printing & bioprinting and holds numerous publications and patents in the field.

Harlan F. Weisman, M.D., is the Executive Chairman of 3DBio Therapeutics. He was formerly the Chief Science and Technology Officer for Medical Devices and Diagnostics at Johnson & Johnson. Prior, Dr. Weisman held the position of Company Group Chairman, Research & Development for Pharmaceuticals. Dr. Weisman joined J&J from Centocor, where he was the President of Research & Development. Harlan was also an Assistant Professor of Medicine and Consultant Cardiologist at Johns Hopkins University School of Medicine. Dr. Weisman received his B.A. in Philosophy from the University of Maryland and his M.D. from the University of Maryland School of Medicine.

Nathaniel Bachrach, Ph.D., is Chief Scientific Officer and Executive Vice President of 3DBio Therapeutics. Prior to 3DBio, Nathaniel was the Vice President of Research & Technology at LifeCell (NASDAQ: LIFC), which was acquired by Allergan. Nathaniel came to LifeCell from Organogenesis. Dr. Bachrach received his Ph.D., as well as B.S. and M.S. degrees, in Mechanical Engineering from Columbia University in New York, where his research focused on cartilage and regenerative medicine.

Larry Bonassar, Ph.D., is a Co-Founder of 3DBio. Larry is the Daljit S. and Elaine Sarkaria Professor of Biomedical Engineering, and holds dual appointments in the Departments of Biomedical and Mechanical Engineering. He is on the Board of Directors of both the International Society for Biofabrication, and the Orthopaedic Research Society. Dr. Bonassar completed postdoctoral fellowships in the Orthopaedic Research Laboratory at the Massachusetts General Hospital and in the Center for Biomedical Engineering at the Massachusetts Institute of Technology. Larry has a received his Ph.D. and M.S. in materials science and engineering from MIT, and his B.S. from Johns Hopkins University.

Hod Lipson, Ph.D., is a Co-Founder of 3DBio. Hod is a Professor of Mechanical Engineering and Data Science at Columbia University in New York. Before joining Columbia University in 2015, Hod spent 14 years as a professor at Cornell University. Dr. Lipson’s work includes the development of seminal aspects of 3D printing with non-traditional materials. Hod is the co-author of the award winning book “Fabricated: The New World of 3D printing” and has published over 300 scholarly articles. Dr. Lipson received his Ph.D. in 1999 from the Technion – Israel Institute of Technology, followed by a postdoc at Brandeis University and MIT.

Colin has 15 years of combined experience helping companies navigate capital markets as an advisor, investor, partner and leader. At 3DBio, he builds on that experience to lead the company’s finance department spanning strategy, FP&A, corporate and business development.

Prior to 3DBio, Colin worked with companies on public markets readiness to prepare for and evaluate fundraising opportunities across both traditional and non-traditional paths. Before that, he worked as a portfolio manager and analyst poring over companies’ financial statements and strategies to allocate capital across public equities.

Colin started his career at Bank of America Merrill Lynch and UBS and holds a Bachelor’s degree from Princeton University and an M.B.A. from Columbia Business School.

Harlan F. Weisman, M.D., is the Executive Chairman of 3DBio Therapeutics. He was formerly the Chief Science and Technology Officer for Medical Devices and Diagnostics at Johnson & Johnson. Prior, Dr. Weisman held the position of Company Group Chairman, Research & Development for Pharmaceuticals. Dr. Weisman joined J&J from Centocor, where he was the President of Research & Development. Harlan was also an Assistant Professor of Medicine and Consultant Cardiologist at Johns Hopkins University School of Medicine. Dr. Weisman received his B.A. in Philosophy from the University of Maryland and his M.D. from the University of Maryland School of Medicine.

Daniel Cohen, Ph.D., is the CEO and Co-founder of 3DBio Therapeutics. Prior to 3DBio, Daniel was an Engagement Manager at McKinsey & Company in New York, where he focused on manufacturing, industrials, healthcare, and 3D printing. He received his Ph.D., as well as B.S. and M.S. degrees, in Mechanical Engineering from Cornell University, with minors in Biomedical and Electrical Engineering. Dr. Cohen was awarded both the National Science Foundation Graduate Research Fellowship, and the Department of Homeland Security Graduate Fellowship. At Cornell, he focused on bioprinting technology, completing his doctoral dissertation on 3D printing & bioprinting and holds numerous publications and patents in the field.

Dr. Barer is the Chairman of Teva. From 1987 to 2011, he served in top leadership roles at Celgene Corporation, including as Executive Chairman from 2010 to 2011, Chairman and CEO from 2007 to 2010, CEO from 2006 to 2010, President and Chief Operating Officer from 1994 to 2006 and President from 1993 to 1994. Prior to that, he was a founder of the biotechnology group at the chemical company Celanese Corporation, which was later spun off as Celgene. Dr. Barer received his Ph.D. in organic and physical chemistry from Rutgers University and his B.S. in chemistry from Brooklyn College of the City University of New York.

Scott most recently served as a Vice President of Research and Development at AbbVie (ABBV), functioning also as the Chief Scientific Officer of the Stemcentrx division in South San Francisco, CA until July 2018. Scott co-founded Stemcentrx in 2008, growing the company to 160 employees with numerous clinical assets launched by 2016 when the company was acquired by AbbVie for $6.2B. Prior to founding Stemcentrx in 2008, Scott was one of the first scientists at OncoMed Pharmaceuticals, where he spearheaded the identification and characterization of solid tumor cancer stem cells. Scott received his BS in Biochemistry & Molecular Biology from the University of Minnesota-Duluth, a Master’s Degree in Molecular Pathobiology from the University of Alabama-Birmingham, and his doctorate in Immunology & Cancer Biology from the University of Minnesota. Scott moved to California in 2002 to postdoc at Stanford University with stem cell pioneer Irv Weissman, and in 2005 was recognized by the British Council as one of eight outstanding young US-based researchers in the field of stem cell biology.

Kevin Slawin, MD. is the Founder and Managing Partner of Rapha Capital Management, LLC. He is a successful and experienced oncologic and robotic surgeon, biotech consultant, investor, and founder focusing on disruptive technologies in oncology, T cells and immunotherapy, as well as other breakthrough healthcare technologies. He is the founder of Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) leading Bellicum to a successful $161 million IPO in December, 2014. He also plays a guiding role in several of the investments managed by Rapha Capital in certain companies, serving as a board member at 3DBio Therapeutics, Inc. (https://3dbiocorp.com/), FIZE Medical, Inc. (https://fizemedical.com), Demeetra AgBio, Inc. (https://demeetra.com) and Imagin Medical, Inc. (https://imaginmedical.com). He served as a board member and interim CEO of portfolio company AsclepiX Therapeutics, Inc. (https://asclepix.com) in 2020, engineering their $35 million Series A financing led by Perceptive Xontogeny Venture Fund in mid 2020. Rapha Capital Management manages thirteen legacy SPIVs, Rapha Capital Investment I – XIII. Rapha Capital Management will be offering alternative asset management services to its inaugural venture capital fund, which will be the vehicle for all future investments managed by Rapha Capital Management.

He is also the founder and CEO of Ponce Therapeutics, Inc. (https://poncetherapeutics.com), which reunites the team that founded Bellicum Pharmaceuticals and is retooling their original cell control technology with state-of-the-art advances towards creating anti-aging products based on a scientific foundation, and DELiver Therapeutics, Inc. (https://delivertherapeutics.com), which is using novel, high throughput screening technologies to deliver therapeutics to address the most difficult problems in clinical medicine. Both have R&D facilities located at K2Bio in Houston (https://www.k2-biolabs.com/), a coworking research facility for biotech and pharma startups recently opened in Houston, where he is a co-founder, investor, and board member.

Slawin graduated magna cum laude with a Bachelor of Arts degree in Biochemistry from Columbia University, where he was inducted into Phi Beta Kappa. He earned his medical degree in 1986 from Columbia College of Physicians and Surgeons and was elected to the Alpha Omega Alpha honor society. He trained in General Surgery and then Urology at the Mount Sinai Hospital and at Squier Urologic Clinic at Columbia Presbyterian Hospital, both in NYC. Later, he was awarded a two-year fellowship, from 1992-1994, as an American Foundation of Urologic Disease (AFUD) scholar at Baylor College of Medicine to continue to study the development and treatment of prostate cancer under the tutelage of renowned prostate cancer surgeon and thought leader, Dr. Peter Scardino. Slawin joined the Baylor College of Medicine as Director of The Baylor Prostate Center in 1994 and was appointed the Dan Duncan Family Professor in Prostate Cancer and Prostatic Diseases in 2003, established by the well-known Houston oil man and philanthropist of the same name. He is co-Inventor of the FDA-approved “prostate health index (phi)” test licensed and marketed by Beckman Coulter and utilized around the world. He has published extensively in top medical and scientific journals including the Journal of the American Medical Association (JAMA), Journal of the National Cancer Institute (JNCI), and the New England Journal of Medicine (NEJM). He has also been routinely listed in America’s Top Doctors for Cancer (Castle Connolly Medical) and The Best Doctors in America (Woodward/White). In 2003, he was awarded the F. Brantley Scott, Jr., Award for Innovation and Creativity in Urology.

Michael G. Bator is the founder of Certus Advisory. Mr. Bator previously was Chief Financial Officer for Trek Therapeutics, Consultant at The Boston Consulting Group, Managing Director at Healthcare Research Systems, and Managing Director at Jennison Associates. Michael G. Bator received an undergraduate degree from Princeton University and an MBA from The Wharton School of the University of Pennsylvania.